ARTICLE SUMMARY:
Approxima aims to treat the root cause, not just the valvular symptoms, of tricuspid regurgitation, with a novel minimally invasive treatment.
The last frontier in structural heart disease is the tricuspid valve, the next target for transcatheter treatment, after the established success of transcatheter aortic valve replacement (TAVR) and the inroads made for transcatheter mitral valve devices. Although severe tricuspid regurgitation is associated with mortality rates of 40-70% within one to four years, the majority of these patients remain untreated for several reasons, including the high risk of surgical interventions in this population.
